You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Granules India receives USFDA approval for Dofetilide capsules

Capital Market 

Granules India announced that the USFDA has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc. for dofetilide capsules.

Dofetilide capsules are bioequivalent to the reference listed drug product of Tikosyn capsules of Pfizer Inc. The capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. They are also indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.

The product would be manufactured at the GPI facility located in Chantilly, Virginia, USA and is expected to be launched shortly. Granules now has a total of 45 ANDA approvals from US FDA (43 Final approvals and 2 tentative approvals).

According to IQVIA Health, dofetilide capsule products had U.S. sales of approximately $39 million for the most recent twelve months ending in August 2021.

Shares of Granules India were trading 1.05% lower at Rs 325 on BSE.

Granules India is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad. The drug company posted a 7.9% rise in consolidated net profit to Rs 120.2 crore on a 15.5% increase in net sales to Rs 849 crore in Q1 FY22 over Q1 FY21.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, October 18 2021. 15:00 IST